According to our report, the size of the North American insulin delivery devices market is predicted to worth USD 18.48 billion by 2026, from USD 13.18 billion in 2021. The market is growing at a CAGR of 6.99% from 2021 to 2026.
The insulin delivery devices market is solely dependent on the growing population of people with diabetes. There has been an incredible rise in the prevalence of diabetes in hospitals in the North American area in recent years. Insulin in North America maintains blood sugar levels and is vital for people with type I diabetes & type II diabetes. Insulin delivery systems have been helped to evolve over the past few years. Such machines are used instead of the oral route of administration to administer insulin doses via the parenteral route.
Insulin delivery systems facilitate the level of insulin absorption from the injection site into the bloodstream to trigger insulin's rapid pharmacological effect among the most widely used insulin delivery devices like insulin syringes, insulin pens, pen needles for insulin, insulin pumps, and insulin jet injectors.
The growth of the demand for diabetes care devices in the region is mainly due to the increasing geriatric population and rapid developments in diabetes care devices.
However, high costs of diabetes treatment services and the risks associated with insulin delivery systems are likely to harm market growth. Strict regulatory laws and regulations for product authorization and minimal penetration of advanced insulin delivery systems in this area also restrict the growth of the North American market for insulin delivery devices. On the other hand, cost-effective pen needle design will have a positive influence on the expansion of the demand for diabetes care devices in North America in the years to come.
This research report on the North American Insulin Delivery Devices Market has been segmented and sub-segmented into the following categories:
By Type:
By Application:
By Country:
Based on the region, The U.S. insulin delivery devices market accounted for a more significant share of the North American market in the last few years. On the other hand, Canada is expected to grow at a more considerable CAGR throughout the forecast period. As per the Centers for Disease Control and Prevention (CDC), last year, 30.3 million people in the U.S. were diagnosed with diabetes, including 23.1 million women, and 7.2 million patients left undiagnosed. Thus, high diabetes prevalence and significant diagnostic rates through easy accessibility of technologically sophisticated devices further fuel the market's regional growth.
Companies playing a dominant role in the North American Insulin Deliver Devices Market profiled in this report are Becton, Dickinson, and Company (U.S.), Sanofi (France), Novo Nordisk A/S (Denmark), Julphar (U.A.E.), Eli Lilly and Company (U.S.), Biocon Ltd. (India), Ypsomed AG (Switzerland), Wockhardt Ltd. (India), B. Braun Meselgen AG (Switzerland) and Biodel Inc. (U.S.).
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Introduction
5.2 Type
5.2.1 Introduction
5.2.2 Insulin Syringes
5.2.3 Insulin Pens
5.2.4 Insulin Pen Needles
5.2.5 Insulin Pumps
5.2.6 Insulin Jet Injectors
5.3 Application
5.3.1 Introduction
5.3.2 Type I Diabetes
5.3.3 Type II Diabetes
6. Geographical Analysis
6.1 Introduction
6.2 United States
6.3 Canada
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Sanofi (France)
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Novo Nordisk A/S (Denmark)
8.3 Eli Lilly and Company (U.S.)
8.4 Biocon Ltd. (India)
8.5 Julphar (U.A.E.)
8.6 Ypsomed AG (Switzerland)
8.7 Becton, Dickinson and Company (U.S.)
8.8 Wockhardt Ltd. (India)
8.9 B. Braun Meselgen AG (Switzerland)
8.10 Biodel Inc. (U.S.)
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
